Your browser is no longer supported. Please, upgrade your browser.
Akebia Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.97 Insider Own1.09% Shs Outstand143.32M Perf Week-1.61%
Market Cap436.55M Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float142.97M Perf Month-0.97%
Income-390.90M PEG- EPS next Q-0.40 Inst Own78.80% Short Float16.60% Perf Quarter-16.55%
Sales308.20M P/S1.42 EPS this Y4.50% Inst Trans9.48% Short Ratio3.73 Perf Half Y-75.32%
Book/sh2.22 P/B1.37 EPS next Y62.00% ROA-52.50% Target Price- Perf Year-60.80%
Cash/sh1.88 P/C1.62 EPS next 5Y- ROE-105.70% 52W Range2.09 - 13.71 Perf YTD8.93%
Dividend- P/FCF- EPS past 5Y21.70% ROI-59.40% 52W High-77.75% Beta1.93
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin59.30% 52W Low45.93% ATR0.16
Employees360 Current Ratio2.20 Sales Q/Q-34.80% Oper. Margin- RSI (14)51.84 Volatility4.99% 4.95%
OptionableYes Debt/Eq0.00 EPS Q/Q8.90% Profit Margin- Rel Volume0.66 Prev Close3.17
ShortableYes LT Debt/Eq0.24 EarningsNov 05 BMO Payout- Avg Volume6.37M Price3.05
Recom2.20 SMA201.98% SMA504.70% SMA200-57.27% Volume4,199,686 Change-3.79%
Nov-14-19Reiterated Needham Buy $18 → $15
Aug-06-19Reiterated H.C. Wainwright Buy $19 → $17
Jul-11-19Reiterated H.C. Wainwright Buy $23 → $21
May-02-19Initiated JP Morgan Overweight $12
Mar-20-19Initiated Citigroup Neutral $9
Sep-07-18Resumed Morgan Stanley Equal-Weight
Aug-10-18Reiterated Needham Buy $20 → $18
Jun-06-18Reiterated H.C. Wainwright Buy $24 → $22
Dec-19-17Initiated Piper Jaffray Overweight $26
Dec-07-17Initiated BTIG Research Buy $30
Sep-15-17Initiated RBC Capital Mkts Sector Perform $17
Jul-10-17Reiterated H.C. Wainwright Buy $25 → $24
Apr-27-17Reiterated Needham Buy $14 → $18
Apr-27-17Reiterated H.C. Wainwright Buy $18 → $21
Dec-27-16Reiterated H.C. Wainwright Buy $17 → $18
Dec-20-16Reiterated JMP Securities Mkt Outperform $16 → $19
Nov-15-16Initiated Aegis Capital Buy
Sep-29-16Initiated Brean Capital Buy
Mar-16-16Reiterated Needham Buy $18 → $14
Jan-21-16Initiated Credit Suisse Neutral
Jan-06-21 08:00AM  
Jan-05-21 04:05PM  
Jan-04-21 08:00AM  
Dec-16-20 02:16PM  
Dec-09-20 08:00AM  
Dec-02-20 04:05PM  
Nov-24-20 08:00AM  
Nov-18-20 09:37AM  
Nov-16-20 08:30AM  
Nov-12-20 08:40AM  
Nov-10-20 05:01AM  
Nov-07-20 07:18AM  
Nov-05-20 11:31PM  
Nov-03-20 04:05PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-23-20 11:15AM  
Oct-22-20 05:05PM  
Oct-13-20 08:40AM  
Oct-09-20 04:49PM  
Oct-08-20 08:54AM  
Oct-02-20 04:05PM  
Sep-29-20 05:27PM  
Sep-26-20 08:50AM  
Sep-08-20 08:00AM  
Sep-04-20 12:55PM  
Sep-03-20 11:55AM  
Sep-02-20 04:05PM  
Aug-26-20 08:41AM  
Aug-12-20 07:08AM  
Aug-10-20 05:55PM  
Aug-07-20 09:30AM  
Aug-03-20 08:00AM  
Jul-14-20 10:32AM  
Jul-06-20 09:37AM  
Jul-02-20 04:05PM  
Jun-29-20 07:40AM  
Jun-23-20 01:22PM  
Jun-22-20 08:00AM  
Jun-18-20 04:01PM  
Jun-16-20 11:30AM  
Jun-12-20 12:00PM  
Jun-10-20 08:00AM  
Jun-02-20 04:30PM  
May-27-20 02:38AM  
May-26-20 08:00AM  
May-21-20 04:05PM  
May-19-20 04:05PM  
May-18-20 08:00AM  
May-13-20 11:37AM  
May-11-20 09:15PM  
May-08-20 08:00AM  
May-07-20 02:15PM  
May-06-20 01:49AM  
May-05-20 06:00PM  
May-04-20 04:30PM  
Apr-28-20 08:00AM  
Apr-17-20 06:44AM  
Apr-14-20 04:41PM  
Apr-10-20 06:31PM  
Apr-07-20 08:00AM  
Apr-02-20 04:30PM  
Mar-23-20 08:00AM  
Mar-15-20 09:28PM  
Mar-12-20 06:20AM  
Mar-10-20 09:15AM  
Mar-03-20 12:30PM  
Mar-02-20 04:05PM  
Mar-01-20 07:04AM  
Feb-25-20 09:41AM  
Feb-24-20 08:00AM  
Feb-04-20 04:05PM  
Jan-31-20 07:10AM  
Jan-06-20 08:00AM  
Jan-03-20 04:05PM  
Jan-01-20 05:14AM  
Dec-11-19 01:57PM  
Dec-10-19 12:22PM  
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOWEN MAXINEDirectorJun 08Sale12.054,56755,03224,133Jun 09 04:17 PM
GILMAN STEVEN CDirectorJun 08Sale12.084,56755,16938,864Jun 09 04:17 PM
Smith CynthiaDirectorJun 08Sale12.104,56755,26137,833Jun 09 04:17 PM
Faulkingham DellCCOJun 01Sale11.586,42674,41373,574Jun 02 04:34 PM
Hadas Nicole R.SVP, Chief Legal OfficerFeb 28Sale8.707,05061,335212,756Mar 02 07:28 PM
Dahan MichelSVP, Chief Operating OfficerFeb 28Sale8.706,97260,656204,960Mar 02 07:29 PM
Amello JasonSVP, CFO & TreasurerFeb 28Sale8.706,97660,691144,642Mar 02 07:27 PM
Tubridy Karen LSVP, Chief Development OfficerFeb 28Sale8.703,45430,05084,679Mar 02 07:26 PM